drugset / Trial / NCT06790095
TRACK-TBI Precision Medicine Part 3 - Option II
Phase 2
Enrolling by invitation
26 enrolled
University of California, San Francisco
U.S. Army Medical Research and Development Command · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drug listed below is approved by the U.S. Food and Drug Administration (FDA) but is being used "off-label" in this study. This means that the drug is not currently approved to treat TBI.
Timeline
- Start
- 2026-06
- Primary completion
- 2026-12
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 5 mg/kg | Intravenous |